리팜피신과 오플로삭신에 내성인 Enterococcus faecalis 균주의 개발

• 영문명: Isolation of the Antibacterial Constituents from Development of Enterococcus faecalis Strains Resistant to Rifampicin and Ofloxacin
• 발행기관: 대한약학회
• 저자명: 이수화(Soo Hwa Lee) 김숙경(Sook Kyung Kim) 정영자(Young Ja Chung) 심미자(Mi Ja Shim) 김병각(Byong Kak Kim) 최응칠(Eung Chil Choi)
• 간행물 정보: 『약학회지』제40권 제3호 (1996년), 351~356쪽, 전체 6쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 1996.06.30

영문 초록

The preparation of Enterococcus faecalis RSI is used as a therapeutics for human intestinal disorders. However, the microbe in this preparation is usually very sensitive to rifampicin and fluoroquinolones. If this preparation is taken with rifampicin or fluoroquinolones, its therapeutic effect can not be expected. E. faecalis RFR11, containing resistance to rifampicin was obtained by MNNG mutation method. Serial passage of E. faecalis RFR11 produced E. feacalis OFR16 on agar with 2-fold minimal inhibitory concentration of ofloxacin produced. E. feacalis OFR16 was resistant to fluoroquinolones up to 8-256 fold higher than that for the original strain. E. faecalis OFR16 also exhibited identical characteristics with the parent strain when they were tested for lactic acid formation and growth inhibition of E. coli MB4-5737 and Shigella sonnei MB4-10411. From in vitro test, it was identified that rifampicin and ofloxacin is not inactivated by certain factors of E. faecalis OFR16. Conclusively. E. faecalis OFR16, rifampicin and fluoroquinolones resistant mutant, is an efficient strain that has insensitivity against rifampicin and fluoroquinolones and original biochemical characteristics of the parent strain.

키워드

Enterococcus faecalis 0FR16 Rifampicin Fluoroquinolones Multi-step mutation.